"Inclusion of these biosimilars is...

 ...contrary to sound clinical evidence and FDA-approved labeling of these products. To be clear, we are not aware of any plans that are requiring Avastin biosimilars prior to use of Avastin as part of step therapy, but some…are encouraging their use."

— Charles Wykoff, M.D., Ph.D., chair of the practice management committee at the American Society of Retina Specialists talked with AIS's RADAR on Specialty Pharmacy about Amgen and Pfizer's Avastin biosimilars, and why they could prove harmful to patients.

 

Subscribers may read the RADAR on Specialty Pharmacy article in which this quote appeared online. Learn more about subscribing to AIS Health's publications.